United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $122.34, for a total transaction of $153,903.72. Following the completion of the transaction, the chief executive officer now directly owns 1,398 shares of the company’s stock, valued at approximately $171,031.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 122.76 on Tuesday. The firm has a market capitalization of $5.34 billion, a PE ratio of 5.94 and a beta of 1.46. United Therapeutics Corp. has a 12-month low of $97.52 and a 12-month high of $164.04. The firm has a 50-day moving average of $124.29 and a 200-day moving average of $116.04.

United Therapeutics Corp. (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, topping the Zacks’ consensus estimate of $3.22 by $1.33. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The business earned $412.60 million during the quarter, compared to analysts’ expectations of $395.15 million. During the same quarter in the previous year, the company earned $2.55 EPS. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Corp. will post $15.82 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in UTHR. Scopia Capital Management LP boosted its position in United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares in the last quarter. Vanguard Group Inc. boosted its position in United Therapeutics Corp. by 1.9% in the second quarter. Vanguard Group Inc. now owns 3,632,002 shares of the biotechnology company’s stock worth $384,702,000 after buying an additional 67,618 shares in the last quarter. BlackRock Fund Advisors boosted its position in United Therapeutics Corp. by 2.7% in the second quarter. BlackRock Fund Advisors now owns 2,217,969 shares of the biotechnology company’s stock worth $234,927,000 after buying an additional 59,026 shares in the last quarter. AJO LP boosted its position in United Therapeutics Corp. by 13.8% in the second quarter. AJO LP now owns 2,141,541 shares of the biotechnology company’s stock worth $226,832,000 after buying an additional 258,931 shares in the last quarter. Finally, State Street Corp boosted its position in United Therapeutics Corp. by 6.6% in the second quarter. State Street Corp now owns 1,968,065 shares of the biotechnology company’s stock worth $208,461,000 after buying an additional 121,355 shares in the last quarter.

Several brokerages recently commented on UTHR. Argus reissued a “hold” rating on shares of United Therapeutics Corp. in a research note on Tuesday, August 23rd. Zacks Investment Research downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. JPMorgan Chase & Co. dropped their price target on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research note on Friday, July 29th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 price target on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Finally, HC Wainwright reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Nine equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $135.64.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.